MARKET WIRETradingView • 1d ago
Jyong Biotech Ltd. Estimates – NASDAQ:MENSTradingView report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
Why MENS Stock slipped -0.53% Today — RQD Quant Desk Flash
$1.87 -0.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.86
Jyong Biotech Ltd. (MENS) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $142.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MENS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MENS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Jyong Biotech Ltd. (NASDAQ: MENS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.87 (-0.53% 1D, market cap $142.9M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MENS compare to MSLE and RNA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MENS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.8%. By comparison, MSLE (Satellos Bioscience Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $142.2M) and RNA (Atrium Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $141.5M). Among the 5-stock peer group, MENS leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MENS?
▼
Per MENS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001954488), Jyong Biotech Ltd. generated $7.3M in revenue (+26.8% YoY), -$4.7M in net income, and -$3.0M in free cash flow against $20.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.86 (-0.29%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MENS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY MENS SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.04-8.8% Next Q
41
Q2 (-2Q)Grade E$1.86+2.7% Next Q
38
Q3 (-1Q)Grade E$1.91-2.1% Next Q
36
CurrentGrade E$1.87-8.9% Hist 90D α
33
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MENS Turnaround Squeeze
While MENS currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.06) and Max Pain ($1.96) forces dealer call-delta covering toward $47.25.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MENS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MENS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MENS Stock slipped -0.53% Today — RQD Quant Desk Flash
Jyong Biotech Ltd. (MENS) slipped -0.53% to $1.87, trading at 2% of its 52-week range ($1.43 – $45). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.43 – $45) with RSI-14 at 45.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.87 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: MENS Exhibits 4.98x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live MENS Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, CaliforniaYahoo Finance report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
About 35% of U.S. men actively managed for enlarged-prostate symptoms get no drug treatmentStock Titan report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance UK • 1d ago
Jyong Biotech Ltd. (MENS) Seasonal returns chartYahoo Finance UK report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Unusual Volume Stocks & Volume Spikes TodayTradingKey report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 2d ago
Nautilus Biotechnology (NAUT) Slips 3.56% to $2.17, Drifting Toward Key Support - Up Down Volumehttps://www.siam.in/ report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
High Dividend Yield Stocks for IncomeTradingKey report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 18d ago
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug CandidatesJyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced th
MARKET WIREBenzinga • 19d ago
Jyong Biotech Plans Potential Texas Manufacturing Facility And U.S. Operations Center To Support Future Commercialization Of Drug CandidatesJyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics,
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MENS)
- ✓Walkthrough of MENS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MENS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.37%▼ DESCENDING CHANNEL
2026-11-03O $1.88H $1.88L $1.87C $1.87VOL 18.8K
RES: $2.15SUP: $1.46SMA50: $2.06SMA200: $2.14
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MENS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +26.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on MENS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MENS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MENS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MENS)
Health Care Rank #686 of 1015
⚔️ MSLE vs MENS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MENS vs. MSLE, RNA, DERM, NGEN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Jyong Biotech Ltd. (MENS) ranks #686 by composite RQD confidence (33/100, grade E) and #609 by equity capitalization ($142.9M). Within this direct 5-issuer industry benchmark cohort, MENS leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. MSLE currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MENS at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MENS
ACTIVE
Jyong Biotech Ltd. | E | 33/100 | — | — | -28.8% | -0.53% | $142.9M | Benchmark Subject |
| MSLE Satellos Bioscience Inc. | D | 46/100 | — | — | — | -4.48% | $142.2M | /msle-vs-mens → |
| RNA Atrium Therapeutics Inc. | D | 44/100 | — | — | — | +3.39% | $141.5M | /rna-vs-mens → |
| DERM Journey Medical Corporation | E | 16/100 | — | 65.8% | -19.5% | -7.35% | $145.9M | /derm-vs-mens → |
| NGEN NervGen Pharma Corp. | D | 45/100 | — | — | — | -1.46% | $147.4M | /ngen-vs-mens → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001954488 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jyong Biotech Ltd. (MENS) reported GAAP revenue of $7.3M (+26.8% vs. FY2024 revenue of $5.8M , and -6.8% cumulative change since FY2023) , GAAP net income of -$4.7M, operating cash flow of -$3.0M, and free cash flow of -$3.0M (+16.1% YoY). On the balance sheet, MENS closed FY2025 with $20.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.3M | -$4.7M | -$3.0M | -$3.0M | $20.8M | — |
| FY2024 (FY) | 2024-12-31 | $5.8M | -$3.0M | -$3.6M | -$3.6M | $6.4M | — |
| FY2023 (FY) | 2023-12-31 | $7.8M | -$4.4M | -$2.6M | -$2.6M | — | — |
3. MENS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MENS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Jyong Biotech Ltd. (NASDAQ: MENS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.87 (-0.53% 1D, market cap $142.9M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
How does MENS compare to MSLE and RNA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MENS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.8%. By comparison, MSLE (Satellos Bioscience Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $142.2M) and RNA (Atrium Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $141.5M). Among the 5-stock peer group, MENS leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MENS?
Per MENS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001954488), Jyong Biotech Ltd. generated $7.3M in revenue (+26.8% YoY), -$4.7M in net income, and -$3.0M in free cash flow against $20.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MENS trading relative to its 50-day, 200-day, and 52-week technical levels?
MENS last traded at $1.87 (-0.53% on volume of 26,637 shares), positioning the stock -9.22% below its 50-day simple moving average ($2.06) and -12.62% below its 200-day simple moving average ($2.14). Across its 52-week range of $1.43 to $45.00, MENS sits at the 1.0% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.64 to $2.10).
ROARABLE RATING BRIEF • RQD 33/100 (E)
✓ SEC XBRL & RQD VERIFIED
MENS — Jyong Biotech Ltd.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Jyong Biotech Ltd. (MENS) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.87 (-0.53% 1D, market capitalization $142.9M).
- Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -28.8%, gross margin of —, operating margin of —, and free cash flow yield of -2.13%.
- Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Jyong Biotech Ltd. (MENS) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile reports a market capitalization of $0.1B. — for product lines, customer base, or revenue model.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Jyong Biotech Ltd. (MENS) reported $7.3M in annual revenue (up from $5.8M in FY2024, +26.8% YoY) and -$4.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($7.8M revenue, -$4.4M net income) through FY2025, MENS scaled operating cash flow to -$3.0M and free cash flow to -$3.0M, backed by $20.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.13% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $1.43 – $45.00 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
— The Butterfly Supply-Chain Graph lists no upstream or downstream dependencies, no sector-correlation links, and no proprietary signals for MENS, so second-order ripple effects cannot be mapped from the provided material.
- Key Question #1: Can MENS sustain or expand its — operating margin and -28.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $7.3M and free cash flow of -$3.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is MENS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
MENS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Jyong Biotech Ltd. (MENS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 1d ago
Jyong Biotech Ltd. Estimates – NASDAQ:MENS TradingView report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California Yahoo Finance report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
About 35% of U.S. men actively managed for enlarged-prostate symptoms get no drug treatment Stock Titan report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
Jyong Biotech Ltd. (MENS) Seasonal returns chart Yahoo Finance UK report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Unusual Volume Stocks & Volume Spikes Today TradingKey report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 2d ago
Nautilus Biotechnology (NAUT) Slips 3.56% to $2.17, Drifting Toward Key Support - Up Down Volume https://www.siam.in/ report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
High Dividend Yield Stocks for Income TradingKey report covering Jyong Biotech Ltd. (MENS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MENS Bull vs. Bear Conversation Board — What's Your Call at $1.87?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MENS 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $2.35 (+25.0%)
📌 Pinned Debate The stock trades at $1.91 with a 1.0 beta and a reported Altman Z-Score of 2.5, which sits in a range commonly associated with lower ne
Don't sleep on MENS's setup in Health Care. The stock trades at $1.91 with a 1.0 beta and a reported Altman Z-Score of 2.5, which sits in a range commonly associated with lower near-term distress risk than the Piotroski score alone would suggest.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (33/100) backs up the fundamental quality.
CapAlloc_Nerd 🐂 BULL
@MacroHawk_NYC Agree on the RQD 33/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.88 and keeping dry powder in case we test $1.75.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $1.41 (-25.0%)
Spot @ $1.88 The company reports $0.0M revenue with negative operating income, net income, and free cash flow in all three listed years, and an ROIC
I respect the product at Jyong Biotech Ltd., but the stock at $1.88 is a different story. The company reports $0.0M revenue with negative operating income, net income, and free cash flow in all three listed years, and an ROIC of -28.8%, while the RQD rating places it at E / Strong Sell.. FCF yield is -2.13% and RQD sits at 33/100 (E) — why pay up here when you can wait for next quarter's numbers?